A new medicine for severe breathing problems in ARDS
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
['FUNDING_SBIR_2'] · ILLEXCOR THERAPEUTICS, LLC · NIH-11145630
This research is developing a new medicine to help patients with severe acute respiratory distress syndrome (ARDS) get enough oxygen.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ILLEXCOR THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-11145630 on ClinicalTrials.gov |
What this research studies
Acute respiratory distress syndrome (ARDS) is a serious condition where your lungs cannot provide enough oxygen to your body, leading to severe breathing difficulties. Current treatments, like extra oxygen and breathing machines, have limits and haven't significantly improved survival rates for many years. This project aims to create a new medication that works by helping your red blood cells carry and deliver oxygen more effectively to your tissues. The hope is that this new medicine could prevent critical organ damage and improve outcomes for those suffering from severe ARDS.
Who could benefit from this research
Good fit: This research is focused on developing a treatment for individuals experiencing severe acute respiratory distress syndrome (ARDS) and profound hypoxemia.
Not a fit: Patients with mild breathing issues or those whose respiratory failure is due to heart problems may not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new medication could significantly improve oxygen delivery to vital organs and reduce the high mortality rate associated with severe ARDS.
How similar studies have performed: Current supportive therapies for ARDS have not substantially improved mortality in decades, suggesting this novel pharmacologic approach is largely untested in this specific context.
Where this research is happening
RICHMOND, UNITED STATES
- ILLEXCOR THERAPEUTICS, LLC — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIGHT, DAVID RICHARD — ILLEXCOR THERAPEUTICS, LLC
- Study coordinator: LIGHT, DAVID RICHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Lung Injury, Acute Pulmonary Injury, Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome